Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Paragon Therapeutics / United States — Food and Drug Administration

Paragon Therapeutics & United States — Food and Drug Administration

1 shared events · Importance 3 · Last updated Aug 21, 2025

Importance
3
Shared Events
1
Actions
0
Sentiment
-63.333333333333336
Live sentiment trends, interaction importance charts, and action volume tracking available on the NewsDesk Dashboard
Shared Events (1)
0
Business
Capricor Therapeutics Faces Securities Lawsuits
Paragon Therapeutics: Paragon Therapeutics is facing a class action lawsuit for allegedly providing misleading statements regarding its lead cell therapy candidate drug, deramiocel, which led to a significant stock price decline after the United States — Food and Drug Administration denied its Biologics License Application.
Jul 21, 2025 · 31 articles
NEWSDESK
Explore this relationship live

Track how Paragon Therapeutics and United States — Food and Drug Administration interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.